+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Pharmaceutical Suspension Market Size, Share & Trends Analysis Report By Type, By Distribution Channel, By End User, By Indication (Cancer, Neurological, Infectious Diseases, Gastrointestinal, and Others), By Country and Growth Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 147 Pages
  • February 2024
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5943320
The Latin America, Middle East and Africa Pharmaceutical Suspension Market would witness market growth of 6.1% CAGR during the forecast period (2023-2030).

Pharmaceutical suspension is a liquid dosage form in which solid particulates are dispersed finely throughout a liquid medium. It is a versatile drug delivery system that can be administered orally or parenterally. The uniform dispersion of the solid particles, usually insoluble medications, in the liquid, prevents them from settling. Stability and bioavailability are improved by this formulation, especially for poorly soluble medications. Pharmaceutical suspensions provide advantages like ease of administration, increased patient compliance, and dosage flexibility. Their versatility makes them appropriate for a broad range of medications, contributing to their widespread use in the pharmaceutical sector.

Pharmaceutical suspensions cater to a broad spectrum of patients, making them highly adaptable across various demographic segments. From pediatric patients who prefer liquid formulations to elderly individuals having trouble swallowing, suspensions address the unique needs of different age groups, contributing to their widespread adoption. The solubility challenges associated with certain drugs can limit their therapeutic effectiveness. Pharmaceutical suspensions offer a solution by enhancing the bioavailability of poorly soluble compounds, ensuring that a greater proportion of the drug reaches the systemic circulation. This improved efficacy encourages the adoption of suspensions for drugs with bioavailability concerns.

As per the National Library of Medicine, the Middle East has a high rate of cardiovascular disease (10.1%). In this region, the prevalence of dyslipidemia (43.3%) is double that of hypertension (26.2%) and diabetes mellitus (16%). Multifaceted interventions are desperately needed in this region for CVD primary prevention. Thus, due to these aspects, the pharmaceutical suspension market will expand across the LAMEA region in upcoming years.

The Brazil market dominated the LAMEA Pharmaceutical Suspension Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,679.6 million by 2030. The Argentina market is showcasing a CAGR of 7.2% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 5.8% during (2023 - 2030).

Based on Type, the market is segmented into Parenteral, Oral, and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on End User, the market is segmented into Hospitals and Clinics, Home Care Settings, and Others. Based on Indication, the market is segmented into Cancer, Neurological, Infectious Diseases, Gastrointestinal, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

List of Key Companies Profiled

  • Merck & Co., Inc.
  • Bayer AG
  • Sanofi S.A.
  • Pfizer, Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Glenmark Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly And Company
  • Lupin Limited

Market Report Segmentation

By Type
  • Parenteral
  • Oral
  • Others
By Distribution Channel
  • Drug Store & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers
By End User
  • Hospitals and Clinics
  • Home Care Settings
  • Others
By Indication
  • Cancer
  • Neurological
  • Infectious Diseases
  • Gastrointestinal
  • Others
By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Pharmaceutical Suspension Market, by Type
1.4.2 LAMEA Pharmaceutical Suspension Market, by Distribution Channel
1.4.3 LAMEA Pharmaceutical Suspension Market, by End User
1.4.4 LAMEA Pharmaceutical Suspension Market, by Indication
1.4.5 LAMEA Pharmaceutical Suspension Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Opportunities
3.2.3 Market Restraints
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies Deployed in Pharmaceutical Suspension Market
Chapter 5. LAMEA Pharmaceutical Suspension Market by Type
5.1 LAMEA Parenteral Market by Country
5.2 LAMEA Oral Market by Country
5.3 LAMEA Others Market by Country
Chapter 6. LAMEA Pharmaceutical Suspension Market by Distribution Channel
6.1 LAMEA Drug Store & Retail Pharmacies Market by Country
6.2 LAMEA Hospital Pharmacies Market by Country
6.3 LAMEA Online Providers Market by Country
Chapter 7. LAMEA Pharmaceutical Suspension Market by End User
7.1 LAMEA Hospitals and Clinics Market by Country
7.2 LAMEA Home Care Settings Market by Country
7.3 LAMEA Others Market by Country
Chapter 8. LAMEA Pharmaceutical Suspension Market by Indication
8.1 LAMEA Cancer Market by Country
8.2 LAMEA Neurological Market by Country
8.3 LAMEA Infectious Diseases Market by Country
8.4 LAMEA Gastrointestinal Market by Country
8.5 LAMEA Others Market by Country
Chapter 9. LAMEA Pharmaceutical Suspension Market by Country
9.1 Brazil Pharmaceutical Suspension Market
9.1.1 Brazil Pharmaceutical Suspension Market by Type
9.1.2 Brazil Pharmaceutical Suspension Market by Distribution Channel
9.1.3 Brazil Pharmaceutical Suspension Market by End User
9.1.4 Brazil Pharmaceutical Suspension Market by Indication
9.2 Argentina Pharmaceutical Suspension Market
9.2.1 Argentina Pharmaceutical Suspension Market by Type
9.2.2 Argentina Pharmaceutical Suspension Market by Distribution Channel
9.2.3 Argentina Pharmaceutical Suspension Market by End User
9.2.4 Argentina Pharmaceutical Suspension Market by Indication
9.3 UAE Pharmaceutical Suspension Market
9.3.1 UAE Pharmaceutical Suspension Market by Type
9.3.2 UAE Pharmaceutical Suspension Market by Distribution Channel
9.3.3 UAE Pharmaceutical Suspension Market by End User
9.3.4 UAE Pharmaceutical Suspension Market by Indication
9.4 Saudi Arabia Pharmaceutical Suspension Market
9.4.1 Saudi Arabia Pharmaceutical Suspension Market by Type
9.4.2 Saudi Arabia Pharmaceutical Suspension Market by Distribution Channel
9.4.3 Saudi Arabia Pharmaceutical Suspension Market by End User
9.4.4 Saudi Arabia Pharmaceutical Suspension Market by Indication
9.5 South Africa Pharmaceutical Suspension Market
9.5.1 South Africa Pharmaceutical Suspension Market by Type
9.5.2 South Africa Pharmaceutical Suspension Market by Distribution Channel
9.5.3 South Africa Pharmaceutical Suspension Market by End User
9.5.4 South Africa Pharmaceutical Suspension Market by Indication
9.6 Nigeria Pharmaceutical Suspension Market
9.6.1 Nigeria Pharmaceutical Suspension Market by Type
9.6.2 Nigeria Pharmaceutical Suspension Market by Distribution Channel
9.6.3 Nigeria Pharmaceutical Suspension Market by End User
9.6.4 Nigeria Pharmaceutical Suspension Market by Indication
9.7 Rest of LAMEA Pharmaceutical Suspension Market
9.7.1 Rest of LAMEA Pharmaceutical Suspension Market by Type
9.7.2 Rest of LAMEA Pharmaceutical Suspension Market by Distribution Channel
9.7.3 Rest of LAMEA Pharmaceutical Suspension Market by End User
9.7.4 Rest of LAMEA Pharmaceutical Suspension Market by Indication
Chapter 10. Company Profiles
10.1 Merck & Co., Inc.
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 SWOT Analysis
10.2 Bayer AG
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Segmental and Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Product Launches and Product Expansions:
10.2.6 SWOT Analysis
10.3 Sanofi S.A.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental and Regional Analysis
10.3.4 Research & Development Expense
10.3.5 SWOT Analysis
10.4 Pfizer, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Regional & Segmental Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Acquisition and Mergers:
10.4.6 SWOT Analysis
10.5 Novartis AG
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expense
10.5.5 SWOT Analysis
10.6 AstraZeneca PLC
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Acquisition and Mergers:
10.6.6 SWOT Analysis
10.7 Glenmark Pharmaceuticals Limited
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.7.5 SWOT Analysis
10.8 Teva Pharmaceutical Industries Ltd.
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Product Launches and Product Expansions:
10.8.6 SWOT Analysis
10.9 Eli Lilly And Company
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.9.4 Research & Development Expenses
10.9.5 Recent strategies and developments:
10.9.5.1 Partnerships, Collaborations, and Agreements:
10.9.6 SWOT Analysis
10.10. Lupin Limited
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent strategies and developments:
10.10.5.1 Partnerships, Collaborations, and Agreements:
10.10.5.2 Trials and Approvals:
10.10.6 SWOT Analysis

Companies Mentioned

  • Merck & Co., Inc.
  • Bayer AG
  • Sanofi S.A.
  • Pfizer, Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Glenmark Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly And Company
  • Lupin Limited

Methodology

Loading
LOADING...